Phospholipid analogs against HIV-1 infection and disease

Current Pharmaceutical Design

Volumn 9, Issue 18, 2003, Pages 1441-1451

  Morris Natschke, Susan L ^a   Ishaq, Khalid S ^a   Kucera, Louis S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HIV activity; Lipid drug conjugates; Synthetic phospholipids

Indexed keywords

1 OCTADECANAMIDO 2 ETHOXYPROPYL 3 PHOSPHOCHOLINE; 3 HYDROXY 1 (2 METHOXYETHYL) 2 METHYL 4 PYRIDONE; 3' AZIDO 3' DEOXY 5' (3 DODECYLTHIO 2 DECYLOXYPROPYL)PHOSPHOTHYMIDINE; CD4 ANTIGEN; CHOLESTEROL; CHOLINE DERIVATIVE; CP 92; ENFUVIRTIDE; ETHER LIPID; FATTY ACID; FOZIVUDINE TIDOXIL; GLYCOPROTEIN GP 120; INK 11; INK 14; INK 18; INK 20; NEW DRUG; NUCLEOSIDE ANALOG; PHOSPHATIDIC ACID; PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE; PHOSPHORYLCHOLINE; PHOSPHORYLCHOLINE LIPID; PRODRUG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CELL FUSION; CENTRAL NERVOUS SYSTEM; DRUG CONJUGATION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; LYMPHATIC SYSTEM; MYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ADSORPTION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CLINICAL TRIALS; HIV INFECTIONS; HIV-1; HUMANS; NUCLEOSIDES; PHOSPHOLIPIDS; PRODRUGS; TISSUE DISTRIBUTION; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0037699899     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612033454702     Document Type: Review

References (46)

1. Corbett EL, Steketee RW, Ter Kuile FO, Latif AS, Kamali A, Hayes RJ. HIV-1/AIDS and the control of other infectious diseases in Africa. The Lancet 2002; 359: 2177-2187.
2. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N E J M 2002; 347: 385-394.
3. Cohen J. Confronting the limits of success. Science 2002; 296: 2320-2324.
4. De Clercq E. New anti-HIV agents and targets. Med Res Rev 2002; 22: 531-565.
5. Kucera LS, Iyer N, Leake E, Raben A, Modest EJ, Daniel LW, et al. Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Research Human Retroviruses 1990; 6: 491-500.
6. Krugner-Higby L, Goff D, Edwards T, Iyer N, Neufeld J, Kute T, et al. Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody. Aids Research Human Retroviruses 1995; 11: 705-712.
7. Liu DZ, Morris-Natschke SL, Kucera LS, Ishaq KS, Thakker DRJ. Structure-activity relationships for enhancement of paracellular permeability by 2-alkoxy-3-alkylamidopropylphosphocholines across Caco-2 cell monolayers. J Pharm Sci 1999; 88:1169-1174.
8. Ouyang H, Morris-Natschke SL, Ishaq KS, Ward P, Liu D, Leonard S, et al. Structure-activity relationship for enhancement of paracellular permeability across caco-2 cell monolayers by 3-alkylamido-2-alkoxypropylphosphocholines. J Med Chem 2002; 45: 2857-2866.
9. Lambert DM. Rationale and applications of lipids as prodrug carriers. Eur J Pharm Sci 2000; 11: S15-S27.
10. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Lipids 2002; 35: 27-65.
11. Kucera LS, Piantadosi C, Modest EJ. Novel membrane interactive ether lipids with anti-human immunodeficiency virus activity. In Membrane Interactions of HIV. Wiley-Liss, Inc. 1992; pp329-350.
12. Parang K, Wiebe LI, Knaus EE. Novel approaches for designing 5'-O-ester prodrugs of 3′-azido-2′,3′-dideoxythymidine (AZT). Curr Med Chem 2000; 10: 995-1039.
13. Meyer KL, Marasco Jr. CJ, Morris-Natschke SL, Ishaq KS, Piantadosi C, Kucera LS. In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents. J Med Chem 1991; 33: 1377-1383.
14. Kucera LS, Iyer N, Morris-Natschke SL, Chen SY, Gamus F, Ishaq K, et al. In vitro evaluation and characterization of newly designes alkylamidophospholipid analogues as ant-human immunodeficiency virus type 1 agents. Antiviral Chem Chemother 1998; 9: 157-165.
15. Piantadosi C, Marasco Jr. CJ, Morris-Natschke SL, Meyer KL, Gamus F, Surles JR, et al. Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity. J Med Chem 1991; 33: 1408-1414.
16. Aggarwal SK, Gogu SR, Rangan SR, Agrawal KC. Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem 1990; 33: 1505-1510.
17. Doshi KJ, Islam Q, Gallo JM, Boudinot F D, Hsieh L, Qin Y, et al. Brain targeting of anti-HIV nucleosides. ether prodrugs of 3′-azido-2′,3′-dideoxyuridine (AZdU) and 3′-azido 3′-deoxythymidine (AZT). Antiviral Chem Chemo 1993; 4: 263-269.
18. Herrmann DBJ, Kucera LS, Zilch H, Mertens A, Opitz H.G. BM 21.1290: in vitro evaluation of a potential new anti-AIDS compound. Abstract p64, #Mo.A.1057, XI International Conference on AIDS, Vancouver, BC July 7-12, 1996.
19. Herrmann DBJ, Menachik V, Opitz H-G. Intracellular metabolism of the new anti-AIDS compound fozivudine in isolated human peripheral blood leukocytes. Abstract #175 of the Fall Meeting of the Deutsche Gesellschaft fur Experimentelle und Klinische Pharmakologie und Toxikologie. Arc Pharmacology 1997; 356: R44.
20. Herrmann DBJ, Opitz H-G, Kucera LS. In vitro and in vivo evaluation of the new anti-AIDS compound fozivudine Abstract # 174 of the Fall Meeting of the Deutsche Gesellschaft fur Experimentelle und Klinische Pharmakologie und Toxikologie. Arch Pharmacology 1997; 356: R44.
21. Herrmann DBJ, Opitz H-G, Kucera LS. BM21.1290: evaluation of the antiretroviral activity of a new anti-AIDS drug in-vitro Abstract p92, #149, 4th Conference on Retroviruses and Opportunistic Infections, January 22-26, 1997, Washington, DC.
22. Bogner JR, Boerner D, Muhlhofer A, Thomas-Greber E, Herrmann DB, Hoegl L, et al. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290) Antivir Ther 1997; 2: 249-256.
23. Bogner JR, Roecken M, Herrmann DB, Boerner D, Kaufmann B, Gurtler L, et al. Phase I/II trial with fozivudine tidoxil (BM 21-1290): a 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther 1997; 2: 257-264.
24. Girard P-M, Pegram PS, Diquet B, Anderson R, Raffi F, Tubianna R, et al. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. JAIDS 2000; 23: 227-235.
25. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Foz CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-358.
26. Ernbretsen J, Zupancic M, Ribas JL, Burke A, Pacz P, Tenner-Tacz K, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature. 1993; 362: 359-362.
27. Klecker RW Jr, Collins JM, Yarchoen R, Thomas R, Jenkins JF, Broder S, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407-412.
28. Takasawa K, Terasaki T, Suzuki H, Ooie T, Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol Exp Ther 1997; 282: 1509-1517.
29. Jacob JN, Hesse JW, Shashoua VE. Gamma-aminobutyric acid esters. 3. Synthesis, brain uptake, and pharmacological properties of C-18 glyceryl lipid esters of GABA with varying degree of unsaturation. J Med Chem 1987; 30: 1573-1576.
30. Namane A, Gouyette C, Fillion M-P, Fillion G, Huynh-Dinh T. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J Med Chem 1992; 35: 3039-3044.
31. Hostetlar KY, Richman DD, Sridhar CN, Felgner PL, Felgner J, Ricci J, et al. Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. Antimicrob Agents Chemother 1994: 38: 2792-2797.
32. Manouilov KK, Xu ZS, Boudinot FD, Schinazi RF, Chu CK. Lymphatic targeting of anti-HIV nucleosides: distribution of 2′,3′-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice. Antiviral Res 1997; 34: 91-99.
33. Matsushita T, Ryu EK, Hong CI, MacCoss M. Phospholipid derivatives of nucleoside analogs as prodrugs with enhanced catabolic stability. Cancer Res 1981; 41: 2707-2713.
34. Hong CI, An SH, Schliselfeld L, Buchheit DJ, Nechaev A, Kirisits AJ, et al. Nucleoside conjugates: synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine 5′-diphosphate-1,2-dipalmitins. J Med Chem 1988; 31:1793-1798.
35. Van Wijk GM, Hostetler KY, Kronernan E, Richman DD, Sridhar CN, Kumar R, et al. Synthesis and antiviral activity of 3′-azido-3′-deoxythymidine triphosphate distearoylglycerol: a novel phospholipid conjugate of the anti-HIV agent AZT. Chem Phys Lipids 1994; 70: 213-222.
36. Kucera GL, Goff CL, Iyer N, Morris-Natschke SL, Ishaq KS, Wyrick D, et al. Cellular metabolism in lymphocytes of a novel thio-phospholipid-AZT conjugate with anti-HIV-1 activity. Antiviral Res 2001; 50: 129-137.
37. Bradley MO, Webb NL, Anthony FH, Devanesan P, Witman PA, Hernamalini S, et al. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel Clinical Cancer Res 2001; 7: 3229-3238.
38. Hostetlar KY, Ganesh DK, Beadle JR, Aldern KA, Gardner MF, Border R, et al. Lipid prodrugs of phosphoacids: greatly enhanced antiviral activity of 1-0-octadecyl-snglycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells in vitro. Antiviral Res 1996; 31: 59-67.
39. Ruiter GA, Zerp SF, Bartelink H, van Blitterswijk WJ, Verheij M. Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 1999; 59: 2457-2463.
40. Biscone M, Pierson T, Doms R. Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol 2002; 2: 529-533.
41. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Mathews TJ. Peptides corresponding to a predictive alphahelical domain of human immunodeficiency virus type1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994; 91: 9770-9774.
42. Chan DC, Lim PS. HIV entry and its inhibition. Cell 1998; 93: 681-684.
43. Lu M, Blacklow SC, Kim P S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-1082.
44. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, et al. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. Curr Pharm Des 2002; 8(8): 615-57.
45. Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, et al. Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches. Curr Pharm Des 2002; 8(8): 595-614.
46. Tommi Y. Lipid formulation as a drug carrier for drug delivery. Curr Pharm Des 2002; 8(6): 467-74.